Related Experiment Videos
Vitronectin in clotting factor IX concentrates.
D Josic1, C Kannicht, K Löster
1Octapharma Pharmazeutika Produktionsges m.b.H., Wien, Austria. djuro.josic@octapharma.at
Summary
Plasma-derived factor IX (FIX) concentrates contain multimeric vitronectin impurity. Methods like nanofiltration or size-exclusion chromatography can remove this protein, which requires further physiological investigation.
Area of Science:
- Biochemistry
- Protein purification
- Biotechnology
Background:
- Plasma-derived factor IX (FIX) concentrates are crucial therapeutics.
- Current purification methods, including anion exchange and heparin affinity chromatography, leave residual accompanying proteins.
- Vitronectin, an adhesive glycoprotein, is identified as a major impurity in these FIX concentrates.
Purpose of the Study:
- To identify and characterize impurities in highly purified, plasma-derived factor IX (FIX) concentrates.
- To investigate the form of vitronectin present in FIX concentrates.
- To evaluate methods for removing vitronectin from FIX concentrates and discuss implications for therapeutic use.
Main Methods:
- Anion exchange chromatography
- Heparin affinity chromatography
- Nanofiltration with a crossflow system
- Size-exclusion chromatography
Main Results:
- Vitronectin is the main accompanying protein impurity in FIX concentrates.
- Vitronectin exists exclusively in its multimeric form in FIX concentrates, unlike in plasma.
- Both nanofiltration and size-exclusion chromatography effectively remove multimeric vitronectin.
Conclusions:
- Multimeric vitronectin is a significant impurity in plasma-derived FIX concentrates.
- Effective removal methods, such as nanofiltration and size-exclusion chromatography, are available.
- The physiological impact of administering multimeric vitronectin to patients requires further investigation, and its removal is recommended.